Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ, Morris JC, Fagan AM, Ances BM, Benzinger TL.

Brain. 2016 Aug;139(Pt 8):2249-60. doi: 10.1093/brain/aww139. Epub 2016 Jun 10.

2.

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

3.

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2016 May;139(Pt 5):1551-67. doi: 10.1093/brain/aww027. Epub 2016 Mar 8.

4.

Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.

Chiaravalloti A, Barbagallo G, Ricci M, Martorana A, Ursini F, Sannino P, Karalis G, Schillaci O.

Brain Res. 2018 Jan 1;1678:116-122. doi: 10.1016/j.brainres.2017.10.016. Epub 2017 Oct 21.

PMID:
29066367
5.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

6.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.

Palmqvist S, Mattsson N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2016 Apr;139(Pt 4):1226-36. doi: 10.1093/brain/aww015. Epub 2016 Mar 2.

7.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

8.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM.

Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.

9.

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.

Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2017 Aug 15;157:448-463. doi: 10.1016/j.neuroimage.2017.05.058. Epub 2017 Jun 3.

10.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

11.

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.

Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ, Holtzman DM, Fagan AM, Morris JC, Benzinger TL, Ances BM.

Sci Transl Med. 2016 May 11;8(338):338ra66. doi: 10.1126/scitranslmed.aaf2362.

12.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
13.

Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.

Dumurgier J, Hanseeuw BJ, Hatling FB, Judge KA, Schultz AP, Chhatwal JP, Blacker D, Sperling RA, Johnson KA, Hyman BT, Gómez-Isla T.

J Alzheimers Dis. 2017;60(4):1451-1459. doi: 10.3233/JAD-170511.

14.

Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.

Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2017 May 1;140(5):1499-1512. doi: 10.1093/brain/awx046.

PMID:
28334939
15.

Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

Yakushev I, Muller MJ, Buchholz HG, Lang U, Rossmann H, Hampel H, Schreckenberger M, Fellgiebel A.

Curr Alzheimer Res. 2012 Feb;9(2):241-7.

PMID:
22044023
16.

18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.

Passamonti L, Vázquez Rodríguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ, Sami S, Cope TE, Bevan-Jones WR, Jones PS, Arnold R, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Brain. 2017 Mar 1;140(3):781-791. doi: 10.1093/brain/aww340.

17.

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2017 Dec 1;140(12):3286-3300. doi: 10.1093/brain/awx243.

18.

Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.

Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Aug;11(8):986-93. doi: 10.1016/j.jalz.2015.03.002. Epub 2015 Apr 24.

19.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

20.

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, Mintun MS.

Brain. 2016 May;139(Pt 5):1539-50. doi: 10.1093/brain/aww023. Epub 2016 Mar 2.

PMID:
26936940

Supplemental Content

Support Center